Page 7 - அதே குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article SUZHOU, China, March 11, 2021 /PRNewswire/ Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today top-line results from its investigator-initiated Brazil trial evaluating the efficacy of Proxalutamide relative to standard of care as assessed by the COVID-19 ordinal scale. In the clinical trial, Proxalutamide met the primary endpoint at day 14, demonstrating a reduction of 4.01 in WHO COVID-19 ordinal scale from a baseline of 5.663 to 1.653 in the Proxalutamide arm versus a reduction of 0.25 from a baseline of 5.618 to 5.368 in the control arm with a p value 0.0001. Proxalutamide also demonstrated a reduction in mortality risk by 92% (3.7% vs 47.6%) and shortened median hospital length stayby 9 days (median hospital stay of 5 days vs 14 days).

Andy gorenKarl schmiederAdsuara cadegianiKintor pharmaceuticalsIr teamPr teamWe at kintor pharmaceuticalsSamel groupPrnewswire kintor pharmaceutical limitedPharmaceutical limitedTong youzhiChief executive officerKintor pharmaceuticalIntensive care unitsNorth brazilஆண்டி கோரேன்